



701 West Morse Boulevard • Winter Park, FL 32789 • [407] 629-8121 • fax [407] 629-7250

## IRA SHAFRAN, M.D., A.G.A.F.



A Board Certified Gastroenterologist practicing in the Orlando area since 1979, Dr. Shafran completed his Internal Medicine & GI training at Ohio State University Medical School. He graduated Phi Beta Kappa and was given the John E. Brown, Sr. Award for consistent Excellence. He is recognized as a Fellow of the American Gastroenterological Association (AGA).

During the past several years, he has been on the forefront of researching a Cause & a Cure for Crohn's disease. He continues to pursue ground breaking research, producing numerous publications and becoming internationally renowned for his expertise using novel, successful therapies for Inflammatory Bowel Disease.

Dr. Shafran is acknowledged as one of America's Leading Experts in Inflammatory Bowel Disease, A "Top" Gastroenterologist in the *Guide to Top Doctors* '99, and in the *2006 through present, Guide to Top Physicians*. He has been awarded the prestigious **Bridges-to-Excellence** Recognition by the American Gastroenterological Association ([AGA](#)), designating the Shafran Gastroenterology Center as a Center-of-Excellence for Inflammatory

Bowel Disease Care since 2013. He is considered among the "Top 70 Doctors" in Central Florida according to his peers and featured yearly in the *Orlando Magazine's* issues. Frequently, he can be seen on TV for newsworthy GI developments on America's Health Network and PBS *HealthWeek* and *Dr. G Medical Examiner*. As a leader in his field, Dr. Shafran lectures locally, nationally & internationally. He was featured in *Saturday Evening Post's* May-June 2004 article, [Reducing the Risk of Crohn's Disease](#). *The Orlando Sentinel* highlighted his ongoing work with Crohn's & a bacterial etiology in an article on the front page of their Sunday, December 2, 2007 issue, [Antibiotics offer hope for Crohn's](#). Throughout his career, he has been an outspoken patient advocate & supporter of Patient Rights.

At the Shafran Gastroenterology Center, our associates & staff take great pride in providing our patients with the highest quality medical care in a warm & friendly way, tailoring treatment to meet each patient's specific needs.

---

### EDUCATION

- |                  |  |
|------------------|--|
| <b>1967-1971</b> | B Sc., in Zoology, cum laude; Ohio State University, Columbus, OH    |
| <b>1971-1974</b> | M.D., cum laude; Ohio State University, Columbus, OH                 |
| <b>1974-1975</b> | Medical Internship; Ohio State University Hospital, Columbus, OH     |
| <b>1975-1977</b> | Medical Residency; Ohio State University Hospital, Columbus, OH      |
| <b>1977-1979</b> | Gastroenterology Fellowship; Ohio State Univ. Hospital, Columbus, OH |

## BOARD CERTIFICATION

- 6/1977** American Board of Internal Medicine #61873
- 6/1979** American Board of Internal Medicine, Subspecialty of Gastroenterology #61873

## PROFESSIONAL EXPERIENCE

- 1975-1979** Participated in National Cooperative on Crohn's Disease
- 1979-Present** Private Practice in Gastroenterology in Winter Park, FL  
Dr. Shafran performs procedures at Florida Surgery Center (180 Boston Ave., Altamonte Springs, FL)  
and at Florida Surgery Center (180 Boston Avenue., Altamonte Springs, FL)
- 1979-1996** Assistant Professor-Internal Medicine/Gastroenterology-University South Florida  
Assistant Professor-Internal Medicine/Gastroenterology-Florida Hospital, Orlando, FL
- 1979-1996** Active Medical Staff, Winter Park Memorial Hospital
- 1980-1990** Chairman Department of Endoscopy, Florida Hospital, Orlando, FL
- 1984-1996** Active Medical Staff, South Seminole Community Hospital
- 1992-1997** Chairman Department of Endoscopy, Florida Hospital, Orlando, FL
- 1990-2012** Risk Management Advisor, Florida Hospital, Orlando, FL
- 1990-2000** Founder, Concerned Physicians of America, Non-profit organization asserting the rights of the  
Doctors and the Patients
- 1994-1998** Volunteer Physician, Health Care Clinic for the Homeless, Orlando, FL
- 1997** Special Advisor to Florida Hospital.
- 2000** Assistant Professor-College of Health & Public Affairs-University Central Florida
- 2009-2012** Associate Professor-University of Central Florida Medical School
- 2010-Present** CCFA Board of Directors
- 2015** American Gastroenterological Association Fellow (AGAF)

## ORGANIZATIONS & SOCIETY MEMBERSHIPS

### Current

American Gastroenterologic Association (AGA)  
Florida Society for Gastrointestinal Endoscopy (FMA)  
American Society for Gastrointestinal Endoscopy (ASGE)  
Crohn's & Colitis Foundation of America (CCFA) Board  
National Ileitis and Colitis Foundation Member  
Foundation for Excellence and Ethics in Medicine  
Paratuberculosis Aggressive Research Association  
American Academy of Fellow Physicians Member  
Alpha Epsilon Delta Society  
Phi Beta Kappa  
International Paratuberculosis Association

### Past

American College of Legal Medicine  
American College of Physician Executives  
Orange County Medical Society  
Florida Society of Internal Medicine  
American Society of Internal Medicine  
American Association for the Study of Liver Disease  
American Association for the Study of Liver Disease  
American Society of Microbiology

## EDUCATOR

- Dedicated educator and lecturer to students, colleagues, patients, and the public
- AIDS activist, along with his wife, who is the co-founder of the HIV Awareness Program for the Florida Medical Association and both have lectured & contributed greatly to the cause of AIDS prevention.
- Preceptor
- Teacher in [flexible sigmoidoscopy](#) (certified by ASGE)
- Set up flexible sigmoidoscopy clinic in large teaching hospital, allowing hundreds of residents to learn the skills of flexible sigmoidoscopy.
- Preceptorship enables residents, students, and pharmacy reps to work with and shadow Dr. Shafran
- Instrumental in developing clinical guidelines and algorithms for a variety of internal medicine subspecialties.

## QUALITY ASSURANCE

- Dr. Shafran has participated in QA and continued quality improvement issues since 1979 and has been an active leader in QA in his specialty.
- Served as an independent QA review since 1980, reviewing other gastroenterologists procedures for proctorship and re-certification.
- Participant in regular risk management issues where standard of care issues and medical-legal decision-making violations may occur.

## CURRENT RESEARCH INTERESTS

- [Crohn's Disease and Mycobacterial infection](#)
- Serologic diagnosis of inflammatory bowel disease
- [Antibiotic treatment of Crohn's Disease.](#)

## PUBLICATIONS

Efficacy & Safety of Retreatment with Vedolizumab in Patients with Crohn's Disease (GEMINI 2+LTS)

Sands, B., Shafran, I., Farraye, F.A., et al

*10<sup>th</sup> Congress of European Crohn's & Colitis Organization (ECCO) Barcelona, Spain, February 20, 2015, Oral presentation & Poster Session*

Efficacy & Safety of Retreatment with Vedolizumab in Patients with Ulcerative Colitis (GEMINI 1+ LTS)

Sands, B., Shafran, I., Farraye, F.A., et al

*10<sup>th</sup> Congress of European Crohn's & Colitis Organization (ECCO) Barcelona, Spain, February 20, 2015 Oral presentation & Poster Session*

Open-label investigation of mucosal healing in patients with Crohn's disease treated with Vedolizumab: A case series.

Shafran, I., Burgunder, P.

*13<sup>th</sup> Annual Advances in Inflammatory Bowel Diseases, December 4-6, 2014, Poster Session  
Inflammatory Bowel Diseases. Vol 21, Number 1, January 2015*

Evaluation of Mucosal Healing in Small Bowel Crohn's Disease Treated with Certolizumab Pegol Assessed by Wireless Capsule Endoscopy

Shafran, I., Burgunder, P., DePanicis, R., Fitch, K., Hewit, S., Abbott, L.

*12<sup>th</sup> Annual Advances in Inflammatory Bowel Diseases, December 12-14, 2013, Poster Session  
Inflammatory Bowel Diseases. Vol 20, Number 1, January 2014*

The Use of Serial Wireless Capsule Endoscopy in Treatment Decisions to Improve Outcomes in Small Bowel Crohn's Disease

Shafran, I., Burgunder, P., Kwa, M., Nadar, K.

*12<sup>th</sup> Annual Advances in Inflammatory Bowel Diseases, December 12-14, 2013, Poster Session  
Inflammatory Bowel Diseases. Vol 20, Number 1, January 2014*

Community Experience with Capsule Endoscopy in 98 Patients with Crohn's Disease

Shafran, I., Burgunder, P., Kwa, M.

*12<sup>th</sup> Annual Advances in Inflammatory Bowel Diseases, December 12-14, 2013, Poster Session  
Inflammatory Bowel Diseases. Vol 20, Number 1, January 2014*

Evaluation of Mucosal Healing in Small Bowel Crohn's Disease Treated with Certolizumab Pegol Assessed by Wireless Capsule Endoscopy

Shafran, I., Burgunder, P., DePanicis, R., Fitch, K.

*11<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 13-15, 2012, Poster Session  
Inflammatory Bowel Diseases. Vol 19, Number 1, January 2013*

The Use of Wireless Capsule Endoscopy in Community Practice: An 11 Year Experience

Shafran, I., Burgunder, P., Kwa, M.

*11<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 13-15, 2012, Poster Session  
Inflammatory Bowel Diseases. Vol 19, Number 1, January 2013*

Certolizumab Pegol as Treatment for Crohn's Disease in a Community IBD Practice

Shafran I, Burgunder P, Fakhri F Shafran Gastroenterology Center, Winter Park, FL.

*10<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 1-3, 2011, Poster Session  
Inflammatory Bowel Diseases. Vol 18, Number 1, January 2012*

A Single Center's Experience With Capsule Endoscopy in 74 Patients with Crohn's Disease: Is it Safe?

Shafran I, Burgunder P, Kwa M

*Abstracts from the 76<sup>th</sup> Annual Scientific Meeting of the American College of Gastroenterology  
American Journal of Gastroenterology, Vol. 106, Supplement 2, October 2011*

Gender Differences in Infliximab Durability: A Single Center 13 Year Experience

Shafran I, Burgunder P

*Abstracts from the 76<sup>th</sup> Annual Scientific Meeting of the American College of Gastroenterology  
American Journal of Gastroenterology, Vol. 106, Supplement 2, October 2011*

Open Label Investigation of Mucosal Healing in Patients with Small Bowel Crohn's Disease Treated with Certolizumab Pegol Assessed by Wireless Capsule Endoscopy

Shafran I, Burgunder P, Fagenson, A, Shafran Gastroenterology Center, Winter Park, FL.

*Abstracts from the 76<sup>th</sup> Annual Scientific Meeting of the American College of Gastroenterology  
American Journal of Gastroenterology, Vol. 106, Supplement 2, October 2011*

Efficacy of certolizumab pegol therapy in patients with Crohn's disease.

Shafran I, Al-Maani S, Burgunder P

*Abstracts from the 2010 Inflammatory Bowel Diseases, December 9-12, 2010  
Inflammatory Bowel Diseases, Vol 17, Number 1, January 2011*

Efficacy of adalimumab therapy in patients with Crohn's disease who were unresponsive to or intolerant of infliximab: 6 years of experience in a single gastroenterology center.

Shafran I, Cangemi D, Burgunder P

*Abstracts from the 2010 Inflammatory Bowel Diseases, December 9-12, 2010  
Inflammatory Bowel Diseases, Vol 17, Number 1, January 2011*

Single-center 12 year experience with infliximab

Shafran I, Burgunder P

*Abstracts from the 2010 Inflammatory Bowel Diseases, December 9-12, 2010  
Inflammatory Bowel Diseases, Vol 17, Number 1, January 2011*

Barriers to the use of a mobile and web-based application for tracking inflammatory bowel disease.

Shafran I, Burgunder P, Shafran A, Chew E

*Abstracts from the 2010 Inflammatory Bowel Diseases, December 9-12, 2010  
Inflammatory Bowel Diseases, Vol 17, Number 1, January 2011*

A single center's experience with capsule endoscopy in 65 patients with Crohn's disease: Is it safe?

Shafran I, Burgunder P, Kwa M

*Abstracts from the 2010 Inflammatory Bowel Diseases, December 9-12, 2010  
Inflammatory Bowel Diseases, Vol 17, Number 1, January 2011*

Mobile and web-based application for IBD tracking

I Shafran, P Burgunder, B Shamosh

*8th Annual Advances in the Inflammatory Bowel Diseases, December 3-6, 2009, P0113, Poster Session  
Inflammatory Bowel Diseases, Vol 15, Number S2, December 2009*

Long-term rifaximin treatment for newly diagnosed Crohn's disease

I Shafran, P Burgunder

*8th Annual Advances in the Inflammatory Bowel Diseases, December 3-6, 2009 P0127, Poster Session  
Inflammatory Bowel Diseases, Vol 15, Number S2, December 2009*

Adalimumab therapy for patients with Crohn's disease who are unresponsive to or intolerant of infliximab

I Shafran, P Burgunder

*8th Annual Advances in the Inflammatory Bowel Diseases, December 3-6, 2009 P0126, Poster Session  
Inflammatory Bowel Diseases, Vol 15, Number S2, December 2009*

Does combination therapy using rifaximin with adalimumab improve Crohn's disease activity and mucosal healing?

-A case series

I Shafran, P Burgunder

*8th Annual Advances in the Inflammatory Bowel Diseases, December 3-6, 2009 P0017, Poster Session  
Inflammatory Bowel Diseases, Vol 15, Number S2, December 2009*

Rifaximin maintenance therapy for Crohn's disease.

Ira Shafran MD, P. Burgunder, ARNP, Shafran Gastroenterology Center,

*ACG Annual Scientific Meeting October 23-29, 2009 P1139, Poster Session*

*The American Journal of Gastroenterology, Vol 104, Number S3, pg 358, September 2009*

Monitoring adherence and outcomes in patients with inflammatory bowel disease

Ira Shafran MD, P. Burgunder, ARNP, Shafran Gastroenterology Center,

*ACG Annual Scientific Meeting October 23-29, 2009, P707, Poster Session*

*The American Journal of Gastroenterology, Vol 104, Number S3, pg 481, September 2009*

Evaluation of serology results from patients with inflammatory bowel disease

Ira Shafran MD, P. Burgunder, ARNP, Shafran Gastroenterology Center,

*CG Annual Scientific Meeting October 23-29, 2009, P706, Poster Session*

*The American Journal of Gastroenterology, Vol 104, Number S3, pg 455, September 2009*

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: Results of a phase II dose-finding study.

Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H.

*BMC Gastroenterol. 2009 Mar 20;9(1):22.*

Comparative Analysis of IBD Serology

I Shafran, P Burgunder, T. Aplin

*7th Annual Advances in the Inflammatory Bowel Diseases, December 7, 2008, Oral Presentation*

*Gastroenterology, Vol 134, Number 4, pg A-201, April, 2008*

Tomographic Enterography With Standard Diagnostic Assessments for Detecting Active Crohn's Disease

I Shafran, P Burgunder

*7th Annual Advances in the Inflammatory Bowel Diseases, December 4-7, 2008, P670, Poster Session*

*Inflammatory Bowel Diseases, Vol 14, Number S3, December 2008*

Monitoring Treatment-Specific Adherence and Outcomes in Patients With Ulcerative Colitis

I Shafran, P Burgunder

*7th Annual Advances in the Inflammatory Bowel Diseases, December 4-7, 2008, P0065, Poster Session*

*Inflammatory Bowel Diseases, Vol 14, Number S3, December 2008*

Potential Pathogenic Role of Mycobacterium avium Subspecies paratuberculosis in Crohn's Disease

Ira Shafran, MD, Patricia Burgunder, ARNP

*Inflammatory Bowel Disease, Vol 14, Number 12, pg 1753-1755 December 2008*

Rifaximin Monotherapy Was Effective in Patients with Newly Diagnosed Crohn's Disease

Ira Shafran MD, P. Burgunder, ARNP, Shafran Gastroenterology Center

*September 2009 ACG Annual Scientific Meeting October 3-8, 2008 Poster Session*

*The American Journal of Gastroenterology, Vol 104, Number S3, pg 358,*

Monitoring Patients with Ulcerative Colitis in Community Based Practice to Improve Adherence

Ira Shafran, MD, P. Burgunder, ARNP, Shafran Gastroenterology Center,

*ACG Annual Scientific Meeting October 3-8, 2008, P1070, Poster Session*

*The American Journal of Gastroenterology, Vol 103, Number S1, pg 418, September 2008*

Comparison of Computed Tomographic Enterography with Standard Diagnostic Assessments for Detecting Active Crohn's Disease

Ira Shafran, MD, P. Burgunder, ARNP, Shafran Gastroenterology Center,  
ACG Annual Scientific Meeting October 3-8, 2008, P1070, Poster Session

*The American Journal of Gastroenterology*, Vol 103, Number S1, pg 418, September 2008

Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series.

Shafran I, Burgunder P.

*Am J Gastroenterol*. 2008 Aug;103(8):2158-60.

Anti-mycobacterials and Crohn's disease.

Chamberlin WM, Shafran I.

*Aliment Pharmacol Ther*. 2008 Aug 1;28(3):373-4.

Newly Diagnosed Crohn's Disease: Case Series of Rifaximin Monotherapy

I. Shafran, P. Burgunder, Presented at Crohn's & Colitis Foundation National Research & Clinical Conference  
6<sup>th</sup> Annual Advances in the Inflammatory Bowel Disease, December 6-9, 2007, Poster Session

*Inflammatory Bowel Diseases*, Vol 14, Number S1, January 2008

Computed Tomographic Enterography as a Noninvasive Diagnostic Tool for Active Crohn's Disease

I. Shafran, P. Burgunder, Presented at Crohn's & Colitis Foundation National Research & Clinical Conference  
6<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 6-9, 2007, Poster Session

*Inflammatory Bowel Diseases*, Vol 14, Number S1, January 2008

Private Practice Experience Switching Chronic Stable Ulcerative Colitis (UC) Patients to Mesalamine MMX

J. Hilal, I. Shafran, P. Burgunder, Presented at Crohn's & Colitis Foundation National Research & Clinical Conference  
6<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 6-9, 2007, Poster Session

*Inflammatory Bowel Diseases*, Vol 14, Number S1, January 2008

Assessment of the Validity of Computed Tomographic Enterography for Diagnosing Active Crohn's Disease

I. Shafran, P. Burgunder, Presented at ACG Annual Scientific Meeting, October 12-17, 2007, Poster Session

*The American Journal of Gastroenterology*, Vol 102, Number 9, 635 (S264), September 2007

Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease

I. Shafran, P. Burgunder

Presented at ACG Annual Scientific Meeting, October 12-17, 2007, P500, Poster Session

Interferon beta-1a for Maintenance of Remission in Patients With Crohn's Disease: Results of a Phase II Dose-Finding Study

Claudia Pena Rossi, Stephen B. Hanauer, Gregory F. Bonner, Ratko Tomasevic, John Hunter, Ira Shafran, Hans Graffner  
*BMC Gastroenterology* (2007)

Is Monotherapy with an Oral Antibiotic Useful in Reducing Crohn's Disease Activity?

I. Shafran, P. Burgunder

5<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 1-3, 2006, P082, Poster Session

*The American Journal of Gastroenterology*, Vol 101, Number 9, 635 (S264), September 2006

*Inflammatory Bowel Disease*, Vol 13, Number 5, May 2007

Adjunctive Antibiotic Therapy With Rifaximin May Help Reduce Crohn's Disease Activity

I. Shafran, P. Burgunder

5<sup>th</sup> Annual Advances in the Inflammatory Bowel Diseases, December 1-3, 2006, P081 Poster Session

*Inflammatory Bowel Disease*, Vol 13, Number 5, May 2007

*The American Journal of Gastroenterology*, Vol 101, Number 9, 1096 (S429), September 2006

A Phase 1/2A Trial of STA 5326, an Oral Interleukin-12/23 Inhibitor, in Patients with Active Moderate to Severe Crohn's Disease  
R. Burakoff, CF Barish, D. Riff, R. Pruitt, WY Chey, FA Farraye, I. Shafran, S. Katz, CL Krone, M. VanderVliet,  
C. Stevens, ML Sherman, E. Jacobson, R. Bleday.  
*Inflammatory Bowel Disease* 2006 Jul;12(7):558-565

Efficacy & Tolerability of Rifaximin, a Non-Absorbable, Gut-Selective, Oral Antibiotic in the Treatment of Crohn's Disease: Results of an Open-Label Trial  
I. Shafran, P. Dondelinger, L. Johnson, L. Hamm. R. Murdock, Jr.  
*Current Medical Research Opinion* 2005 Aug;21(8):1165-9

Seroreactivities Against *Saccharomyces cerevisiae* and *Mycobacterium avium* subsp. *paratuberculosis* p35 and p36 antigens in Crohn's Disease Patients  
I. Shafran, C. Piromalli, JW Decker, J. Sandoval, SA Naser, F. El-Zaatari.  
*Digestive Disease Science* 2002 Sept;47(9):2079-81

In Situ identification of mycobacteria in Crohn's disease patient tissue using confocal scanning laser microscopy.  
S.A. Naser, I. Shafran, D. Schwartz, F. El-Zaatari and J. Biggerstaff,  
*Molecular and Cellular Probes*; 2002 Feb;16(1):41-8

[Open clinical trial of Rifabutin and Clarithromycin therapy in Crohn's Disease.](#)

I. Shafran, L. Kugler, F.A.K. El-Zaatari, S.A. Naser, J. Sandoval,  
*Digestive and Liver Disease*; 2002 Jan; 34:22-8

[Mycobacterium avium subsp. Paratuberculosis as one cause of Crohn's Disease](#)

W. Chamberlain, D.Y. Graham, K. Hulten, H.M.T. El-Zimaity, M.R. Schwartz, S. Naser, I. Shafran, F.A.K. El-Zaatari,  
*Aliment Pharmacol Ther* 15:000-000 (2001).

[Full text \(.pdf\)](#)

Use of Short Term Culture for Identification of *Mycobacterium avium* subsp. *Paratuberculosis* in Tissue from Crohn's Disease Patients.  
D. Schwartz, I. Shafran, C. Romero, N. Naser, C. Piromalli, J. Biggerstaff, W. Chamberlain and S.A. Naser,  
*Clinical Microbiology and Infection*. 6:1-6 (2000).

Isolation of *Mycobacterium avium* subsp. *Paratuberculosis* from Breast Milk of Crohn's Disease Patients.  
S. Naser, I. Shafran, D. Schwartz.  
*American Journal of Gastroenterology*. 95(4) 1094-1095 (2000).

[Fistula Healing in MAP Positive Crohn's Disease Patients Following Rifabutin and Macrolide Antibiotic Treatment.](#)

I. Shafran, L. Kugler, J. Sandoval  
(Submitted to DDW: *Gastroenterology*).

[A Comparative Analysis of Anti-Saccharomyces Antibodies \(ASCA\) and p35 and p36 Recombinant Clones for the Diagnosis of Crohn's Disease \(CD\)](#)

I. Shafran, C. Piromalli, S. Naser,  
*Gastroenterology*. 118(4): A697 (2000).

[Cost Analysis of Antibiotic Treatment in Crohn's Disease Patients Serologically Positive for \*Mycobacterium avium\* ss. \*paratuberculosis\*.](#)

I. Shafran, C. Piromalli and J. Davies  
*Gastroenterology* 118(4): A5071 (2000).

[Mycobacterium Identification in Stool Cultures of IBD Patients Serologically Positive for \*Mycobacterium avium\* ss. \*paratuberculosis\*.](#)

I. Shafran M.D, C. Piromalli B.S  
*Gastroenterology* 118(4): A6207 (2000).



[Identification of Mycobacterium avium ss. paratuberculosis in Crohn's Tissue.](#)

I. Shafran, C. Piromalli, C. Romero, D. Schwartz and S. Naser  
*Gastroenterology* 118(4): A1767 (2000).

[Rifabutin and Macrolide Antibiotic Treatment in Crohn's Patients Identified Serologically Positive for Mycobacterium avium ss. paratuberculosis.](#)

I. Shafran, C. Piromalli, S. Naser  
*Gastroenterology* 118(4): A4182 (2000).

Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of *M. avium* subsp. *paratuberculosis*.  
Naser SA, Hulten K, Shafran I, Graham DY, El-Zaatari FA  
*Vet Microbiol* 2000 Dec 20;77(3-4):497-504

[Comparison of Serologic Markers for the Diagnosis of Crohn's Disease.](#)

I. Shafran, M.D., C. Piromalli, F. El-Zaatari, Ph.D.  
*Am J of Gastroenterol.* 94, 2761 (1999).

[Serum sickness-like illness in Crohn's Disease Patients Treated With Antibiotics.](#)

I. Shafran M.D. and C. Piromalli  
*Am J of Gastroenterol.* 94, 2737 (1999).

[Treatment of Crohn's Disease with Rifabutin and Macrolide Antibiotics.](#)

I. Shafran, C. Piromalli  
*Am J of Gastroenterol* 94, 2761 (1999).

[Mycobacterium Avium, SS Paratuberculosis, in Crohn's Disease is an Affirmative.](#)

D. Schwartz, D. Campbell, C. Romero, I. Shafran, S. Naser  
presented at the *American Society of Microbiology Meeting, 99th meeting, Chicago, May of 1999*, poster session.

[In Vitro Evaluation of Anti-Tuberculous Drugs Against M. Avium, Subspecies Paratuberculosis, for Treatment of Crohn's Disease.](#)

D. Campbell, D. Schwartz, C. Romero, I. Shafran, S. Naser  
presented at the *American Society of Microbiology 99th Meeting, May of 1999*, poster session.

[Endoscopic Healing of Crohn's Disease After Antibiotic Treatment.](#)

I. Shafran, C. Piromalli, S. Naser  
*Gastroenterology*, A-929 (1999).

[Humeral Immune Response of Crohn's Patients for Mycobacterium Avium, Subspecies Paratuberculosis.](#)

I. Shafran, W. Fenster, C. Piromalli, C. Romero, D. Schwartz, D. Campbell, F. El-Zaatari  
*Gastroenterology*, A-929 (1999).

[In Vitro Evaluation of Anti-Tuberculous Drugs Against Mycobacterium Avium Subspecies Paratuberculosis for Treatment of Crohn's Disease.](#)

S.A. Naser, W. Fenster, C. Romero, D. Schwartz, C. Piromalli, I. Shafran  
*Gastroenterology*, A-783 (1999).

[Rapid Culturing and PCR Detection of Mycobacterium Avium, SS. Paratuberculosis, from Crohn's Disease Tissue.](#)

S. Naser, W. Fenster, C. Romero, D. Schwartz, C. Campbell, C. Piromalli, I. Shafran  
*Gastroenterology*, A-782 (1999).

[Mycobacterium avium subsp. Paratuberculosis in Crohn's Disease Is Serologically Positive](#)

S. Naser, I. Shafran  
*Clinical and Diagnostic Laboratory Immunology*, 6: 282 (1999).

Specific Seroreactivity of Crohn's Disease Patients Against P 35 and P 36 Antigens of *M. Avium* Subspecies

Paratuberculosis, S.A. Naser, K. Hulten, I. Shafran, D.Y. Graham, F. El-Zaatari,  
presented at the 1999 6th International Colloquium on Paratuberculosis in Melbourne, Australia.

The Use of Combined Antigens for Specific Diagnosis of Crohn's Disease.  
I. Shafran, W. Fenster, S. Ishak, F. El-Zaatari, S. Naser  
presented at the *American Society of Microbiology, 98th General Meeting*, in Atlanta, Georgia, May of 1998.

Clinical Algorithms in Gastroenterology  
Shafran, I.  
1996 [submitted for publication]

Mastering Flexible Sigmoidoscopy and Primer of Flexible Sigmoidoscopy for the Clinician: a CD-ROM  
Shafran, I.  
1996 [submitted for publication]

H. Pylori, An Overview  
Shafran, I.  
Internet Publication for the ASIM Web Page, 1996

Absence of Helicobacter Pylori in Gastric Carcinoma  
Shafran, I. Apter, M.N., Sprung, D.J.  
*Gastrointestinal Oncology*, A597, April, 1996

Gut Digest-Clinical Practice Patient Information Brochures  
Encompassing over 16 different GI issues  
Shafran, I. 1995-Present

Incidence of Adenocarcinoma in Barrett's Esophagus-A Community- Based Study  
Sprung, D.J., Shafran, I., Apter, M.N.  
*Am J of Gastroenterology*, Vol. 90, No 9, Pg 1572, (76) Sept, 1995

Prevalence of Adenocarcinoma of the Esophagus-A Community-Based Study  
Sprung, D.J., Shafran, I., Apter, M.N.  
*Am J of Gastroenterology*, Vol. 90, No 9, Pg 1572, (76) Sept, 1995

Reasons for Exclusion of Patients in Treatment of NANB Hepatitis  
Shafran, I. Apter, M.N., Sprung, D.J.  
*Gastroenterology*, Vol. 108, No.4, Pg. 1167, April 1995

Drug Treatment for Esophageal Spasm  
Shafran, I.  
*Gastroenterology*, Pg 1334, December, 1982

Segmental Esophageal Spasm, A Variant of Diffuse Esophageal Spasm  
Shafran, I., Ellison, C.E., Fromkes, J.  
*Gastroenterology*, Vol. 80, 1979

Esophageal Spasm with Normally Relaxing Hypertensive Lower Esophageal Sphincter  
Ellison, C.E., Shafran, I., Fromkes, J., Thomas, F. Carey, L.C.  
*Current Surgery*, 36 (5) Pg 362-364, Sept 1979

Nutmeg Toxicology  
Shafran, I.  
*New England Journal of Medicine*, Vol. 296:694, 1977

Prostaglandins and Crohn's Disease  
Shafran, I., Mauer, W., Thomas, F.B.  
*New England Journal of Medicine*, Vol. 296:694, 1977

Nutmeg and Medullary Carcinoma of the Thyroid  
Shafran, I., McCrone, D.  
*New England Journal of Medicine*, Vol. 293:1266, 1975

## **RESEARCH EXPERIENCE**

1. A Randomized, Double-Blind, Multi-Center Comparison Study of Medroxyprogesterone in a Subset of Subjects With Mild to Moderate Ulcerative Colitis Who Previously Failed High-Dose Mesalamine Therapy
2. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Patients with Crohn's Disease
3. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Patients with Crohn's Disease
4. A Crohn's Therapy Resource, Evaluation and Assessment Tool (TREAT) Registry
5. Safety and Efficacy of Two Dose Regimens of XXX in Patients with Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
6. Crohn's Disease Seropositive to *Mycobacteria paratuberculosis* Treated with Rifabutin & Macrolide Antibiotics
7. Molecular, Microbiologic, Immunologic investigation of the *Mycobacterium paratuberculosis* Role in Crohn's Disease Etiology
8. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Mesalamine MMX in Patients with Mild to Moderate Ulcerative Colitis
9. A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine MMX (mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission
10. A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mesalamine MMX (mesalazine) Given Twice Daily (2.4g/day) Versus SPD476 Given as a Single Dose (4.8g/day) in Subjects with Acute Mild to Moderate Ulcerative Colitis
11. Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforen Enema, and Antisense Inhibitor of ICAM-1, for the Treatment of Patients with Mild to Moderate Active Ulcerative Colitis
12. A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren in Subjects with Moderately to Severely Active Crohn's Disease with Elevated C-Reactive Protein
13. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Evaluation of the Efficacy and Safety of Zelnorm (6mg BID) Administered Orally for 12 Weeks, in Male Patients with Chronic Constipation
14. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Zelnorm (6mg BID) and Placebo in Female Patients with Dyspepsia
15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nicotine Administered as an Enema for Treatment of Active Mild-to-Moderate Ulcerative Colitis
16. A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, And Efficacy of Intravenous Antegren in Crohn's Disease Subjects Who Have Previously Participated in CD307 Crohn's Disease Studies
17. Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of the Steroid-Sparing Properties of Sargramostim Therapy in Patients with Corticosteroid-Dependent Crohn's Disease
18. Open-Label Trial of Sagromostim, A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease

19. Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim in Patients with Active Crohn's Disease and Prior Treatment Response to 308180
20. A Phase I/IIa Trial of STA5326 in Crohn's Disease Patients with CDAI Scores of 220-400
21. A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease who Have Lost Response or are Intolerant to Infliximab
22. A Multi-Centered, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease
23. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.6G QD to Maintain Remission from Mild to Moderate Ulcerative Colitis
24. Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn's Disease Naïve to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naïve Patients in Crohn's Disease) SONIC
25. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-arm Study of the Efficacy and Safety of OPC6535 Tablets in the Treatment of Subjects With Active Ulcerative Colitis
26. A Phase 3, Multicenter, 52-Week, Open-Label, Extension Study of the Safety and Efficacy of 25mg or 50mg of OPC6535 Oral Tablets in the Treatment of Subjects With Ulcerative Colitis
27. A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral Anti-Interleukin 12 Inhibitor, STA-5326 for the Induction of Clinical Response in Patients with Crohn's Disease
28. A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Different Doses (275, 550, 1100 mg) of Rifaximin Administered BID for either Two or Four Weeks in the Treatment of Patients with Diarrhea-Associated Irritable Bowel Syndrome
29. A Phase III, Multicenter, Randomized, Double-Blind, Actively Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formation and Dosing of Balsalazide Sodium 3.3 G BID vs Asacol 0.8 G TID in Mildly to Moderately Active Ulcerative Colitis.
30. A Phase IIIb Multi-Center, Double Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid Sparing Effect of Certolizumab pegol in Patients with Moderate to Severe Crohn's Disease.
31. A Multi-Center, Open Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody adalimumab in patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab.
32. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis.
33. A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease who have had Inadequate Clinical Response and or Intolerance to Medical Therapy.
34. Clinical Efficacy and Safety of Mesalamine (MAX-002) vs Canasa in the Treatment of Mild to Moderate Ulcerative Proctitis: A Multi-Center, Open-Label, Randomized, Parallel Group, Non-Inferiority Study

35. A Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Study Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid Refractory Ulcerative Colitis
36. A 52 Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Safety and Efficacy of a 12-Week Treatment of Acute Diverticulitis with Asacol 2.4g/day, Followed by a 9 Month Treatment-Free Observation Period
37. A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST120 in Mild to Moderately Active Crohn's Patients with Fistulas
38. Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase II Study of Efficacy and Safety of HPML004 in Subjects with Active Moderate Crohn's Disease
39. A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with (IV Administered) Abatacept in Subjects with Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy.
40. Procurement of Fasting Blood Samples for Use in the Development of a Gastrointestinal Disease Test Panel
41. A Multi-Center, Investigator-Blinded, Randomized, 12-month, Parallel-Group, Non-Inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol Therapy QD vs Divided Dose BID in the Maintenance of Remission of Ulcerative Colitis
42. A 5 Year Registry Study of Humira in Subjects with Moderately to Severely Active Crohn's Disease
43. A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, Durability, and Retreatment Study to Evaluate the Safety and Efficacy of Prochymal (ex vivo cultured adult human mesenchymal stem cells) Intravenous Infusion for the Maintenance and Re-Induction of Clinical Benefit and Remission in Subjects Experiencing Treatment Refractory Moderate to Severe Crohn's Disease
44. A 52 Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Safety and Efficacy of a 12-Week Treatment of Acute Diverticulitis with Asacol 2.4 g/day (400mg Mesalamine Tablet), followed by a 9 Month Treatment-free Observation Period
45. A Phase I-II, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 when administered orally to patients with active mild to moderate Ulcerative Colitis.
46. A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
47. A Phase IIb, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease.
48. A Phase IIIb, Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-Alpha Monoclonal Antibody, Administered Subcutaneously at Weeks 0, 2 and 4 in Subjects with Moderately to Severely Active Crohn's disease.
49. A Phase IIIb, Multinational, Open-Label, Follow-On Trial to C87085 Designed to Assess the Long-Term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-Alpha Monoclonal Antibody, Administered Subcutaneously at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects with Moderately to Severely Active Crohn's Disease Who Have Participated in C87085.

50. A Phase 2/3 Multicenter, Randomized, Placebo Controlled, Double-Blind, Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis.
51. A Phase III, Multicenter, Randomized, Placebo Controlled, Double-Blind, Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis.
52. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Rifaximin 550 mg in the Treatment of Subjects With Non-Constipation Irritable Bowel.
53. A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine.
54. Phase III Study of the Efficacy and Safety of New Oral Budesonide-MMX (CB-01-02) 6mg and 9mg Extended Release Tablet Formulations in Patients with Mild or Moderate, Active Ulcerative Colitis. A Multi-Center, Randomized, Double-Blind, Double-Dummy Comparative Study Versus Placebo, with an Additional Reference Arm Evaluating Asacol 2400mg.
55. A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Evaluate the Efficacy, and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn's Disease Previously Treated with TNF Antagonist Therapy.
56. SECURE (C87075) A Non-Interventional Long-Term Post Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia) for Crohn's Disease
57. An Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients with Small Bowel Crohn's Disease Treated with Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy.
58. A Phase III, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis.
59. A Phase III, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn's Disease.
60. A Phase III, Open Label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease.
61. A Multicenter, Double-Blind, Controlled, Randomized, Parallel Group Comparison Phase IIIA Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis.
62. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2mg/25ml BID for 2 Weeks, Followed by 2mg/25ml QD for 4 Weeks) Versus Placebo in Subjects with Active Mild to Moderate Ulcerative Proctitis (UP) or Proctosigmoiditis (UPS)
63. Double-Blind, dose-response, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs placebo for the prevention of recurrence of diverticulitis.
64. Test-Treat Strategy To Prevent Ulcerative Colitis Relapse Dose Escalation And Remission (DEAR) Study
65. Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing Remicade (infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence.

66. A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease.
67. A Phase III, multicenter, placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of PROCHYMAL (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion for the induction of remission in subjects experiencing treatment-refractory Moderate to severe Crohn's Disease.
68. A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with XXX-936557 in Subjects with Active Ulcerative Colitis (UC)
69. Sequential Dose Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single doses of 3 Different doses of Oral CNDO201 *Trichuris Suis Ova* Suspension (TSO) in Patients with Crohn's Disease
70. A Phase III, Open Label, Multi-Center Study to Assess the Safety and Tolerability of Budesonide Foam In Subjects with Active Ulcerative Proctitis or Proctosigmoiditis
71. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia
72. A Phase III, Open Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
73. Randomized, Double-Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Remission in Ulcerative Colitis (Methotrexate Response In Treatment of UC-MERIT-UC)
74. Diet's Role in Exacerbations of Asacol Maintenance (DREAM) A Sub-study of QDiem
75. A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects with Moderate Crohn's Disease
76. A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Crohn's Disease (CD)
77. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II Study To Evaluate The Efficacy And Safety Of 12 Weeks Of Treatment With Two Different Doses Of Oral CNDO 201 *Trichuris Suis Ova* Suspension (TSO) As Compared To Placebo, Followed By A 12 Week Open-Label Treatment Period With TSO, In Patients With Moderately To Severely Active Crohn's Disease
78. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis
79. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis
80. A Multi-Center, Open-Label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis
81. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX mg Extended-release Tablets as Add-on Therapy in Patients with Active, Mild or Moderate Ulcerative Colitis not Adequately Controlled on a Background Oral 5-ASA Regimen
82. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome



83. A Study To Assess Repeat Treatment Efficacy And Safety Of Rifaximin 550 Mg TID In Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
84. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy And Safety Of SAR339658 In Patients With Active Moderate To Severe Ulcerative Colitis (UC). COMPOUND: SAR339658
85. ZA201 – A Phase 2, Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa Rectal Gel (mesalamine plus N-acetylcysteine) in Subjects with Left-sided Ulcerative Colitis. November 2012 – January 2014. *Principal Investigator.*
86. AB1101 – A Multicenter, Double-blind, Placebo-controlled, Ascending-dose, Repeat-dose Safety and Pharmacokinetic Investigation of a Delayed-release, Enteric-coated Capsule formulation of AVX-470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients with Active Ulcerative Colitis. March 2013 – January 2014. *Principal Investigator.*
87. TURANDOT (A7281009) – A Double-blind, Double-dummy, Randomized, Placebo-controlled, Parallel, Dose-Oranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects with Moderate to Severe Ulcerative Colitis. April 2013 – Present. *Principal Investigator.*
88. TURANDOT II (A7281010) – A Multicenter, Open-label, Extension Study to Assess Long-term Safety of PF-00547659 in Subjects with Ulcerative Colitis. April 2013 – Present. *Principal Investigator.*
89. CD-IA-MEDI2070-1147 – A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy. June 2013 – Present. *Principal Investigator.*
90. MA-209 – Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn’s Disease (CD) Subjects Receiving an Immunomodulator (IMM) and/or a Biological Treatment. August 2013 – Present. *Principal Investigator.*
91. LEGACY (P11-282) – A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC). September 2013 – Present. *Principal Investigator.*
92. MAP US (RHB-104-01) – A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease. October 2013 – Present. *Principal Investigator.*
93. PREDICT (F12-119) – A Multicenter Study Evaluating a Practical Index Score for Subjects with Crohn’s Disease Assessing the Absence of Mucosal Ulceration. January 2014 – Present. *Principal Investigator.*
94. HICKORY (GA28950) – A Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients with Moderate to Severe Active Ulcerative Colitis Who are Refractory to or Intolerant of TNF Inhibitors. April 2014 – Present. *Principal Investigator.*  
COTTONWOOD (GA28951) – An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase III Studies. May 2014 – Present. *Principal Investigator.*
95. LAUREL (GA29102) – A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared with Placebo in Patients with Moderate to Severe Active Ulcerative Colitis Who are Naïve to TNF Inhibitors. June 2014 – Present. *Principal Investigator.*

96. RECD3125 – A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease. June 2014 – Present. *Principal Investigator*.
97. RP1208 – a Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease. June 2014 – Present. *Principal Investigator*.
98. SERENE CD (M14-115) – A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regimens in Subjects with Moderately to Severely Active Crohn’s Disease and Evidence of Mucosal Ulceration. July 2014 – Present. *Principal Investigator*.
99. SERENE UC (M14-033) – A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis. July 2014 – Present. *Principal Investigator*.
100. PROgECT (CNT0148UCO2001) – A Phase 2a Open-label study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects with Moderately to Severely Active Ulcerative Colitis. July 2014 – Present. *Principal Investigator*.
101. SERENE CD (M14-347) – A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn’s Disease. September 2014 – Present. *Principal Investigator*.
102. CELESTE (M13-740) – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn’s Disease who have Inadequately Responded to or are Intolerant to Anti-TNF Therapy. March 2015 – Present. *Principal Investigator*.

*Updated: April 30, 2015*